Dr. Tierney joined KemPharm’s board in March 2015. Since February 2020, Dr. Tierney has served as chief executive officer of Pharma Two B, Ltd., a privately held company developing innovative therapeutics based on previously approved drugs for Parkinson disease. From September 2019 until January 2020, Dr. Tierney served as president and chief executive officer of BiopharmX, a dermatology drug development company. From March 2014 until March 2018, Dr. Tierney was president chief executive officer of Icon Bioscience, Inc., a privately held ophthalmology company, which was merged into Psivida, Inc to form Eyepoint Pharmaceuticals. From January 2013 until March 2014, Dr. Tierney was a venture partner at Signet Healthcare Partners, a New York City based life science private equity fund. Dr. Tierney served as president and chief operating officer and as a member of the board of directors of Oceana Therapeutics, Inc., a private specialty pharmaceutical company, from its organization in 2008 through its sale to Salix Pharmaceuticals, Ltd. in December 2011. Dr. Tierney served as the president and chief executive officer and as a member of the board of directors of Valera Pharmaceuticals, Inc., a specialty pharmaceutical company, between August 2000 and April 2007, when Valera completed a merger with lndevus Pharmaceuticals, Inc. From January 2000 to August 2000, Dr. Tierney served as president of Biovail Technologies, a division of Biovail Corporation, a Canadian drug delivery company. From March 1997 to January 2000, Dr. Tierney was senior vice president of drug development at Roberts Pharmaceutical Corporation and from December 1989 to March 1997, Dr. Tierney was employed by Elan Corporation, a pharmaceutical company, in a variety of management positions. Dr. Tierney is also a director of Catalyst Pharmaceuticals, Inc., BiopharmX and Bimeda, Inc., a private global veterinary pharmaceutical company. Dr. Tierney received his medical degree from the Royal College of Surgeons in Dublin, Ireland and was subsequently trained in internal medicine.
What is David S. Tierney's net worth?
The estimated net worth of David S. Tierney is at least $0.00 as of December 12th, 2023. Dr. Tierney owns 333,541 shares of Zevra Therapeutics stock worth more than $0 as of March 28th. This net worth approximation does not reflect any other investments that Dr. Tierney may own. Learn More about David S. Tierney's net worth.
How do I contact David S. Tierney?
Has David S. Tierney been buying or selling shares of Zevra Therapeutics?
David S. Tierney has not been actively trading shares of Zevra Therapeutics during the past quarter. Most recently, on Wednesday, May 25th, David S. Tierney bought 2,000 shares of Zevra Therapeutics stock. The stock was acquired at an average cost of $4.39 per share, with a total value of $8,780.00. Following the completion of the transaction, the director now directly owns 5,835 shares of the company's stock, valued at $25,615.65. Learn More on David S. Tierney's trading history.
Who are Zevra Therapeutics' active insiders?